HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday 19 November 2018

October’s CEAs.....

We’ve completed our quick search for CEA’s published last month.   In the right-hand column of this blog is a CEA Archive of all records.  Below are those in our areas of interest.
  • Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, et al. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer epidemiology. 2018;57:60-7.
  • Giorgakoudi K, O'Sullivan C, Heath PT, Ladhani S, Lamagni T, Ramsay M, et al. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study. Vaccine. 2018.
  • Hofer F, Kauczor HU, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. Lung cancer (Amsterdam, Netherlands). 2018;124:189-98.
  • Leal J, Manetti S, Buchanan J. The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study. PharmacoEconomics. 2018;36(10):1263-72.
  • Mistry H, Mason J. Diagnostic Assessment Reviews: is cost-effectiveness analysis helpful or necessary? Journal of health services research & policy. 2018;23(4):222-42.
  • Rosenbloom J, Lewkowitz A, Sondgeroth K, Hudson J, Macones G, Cahill A, et al. Antenatal corticosteroid administration in late-preterm gestations: a cost-effectiveness analysis. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2018:1-191.
  • Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018;10(14):1241-52.
  • Tubeuf S, Saloniki EC, Cottrell D. Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England. PharmacoEconomics. 2018.